Avadel Pharmaceuticals (AVDL)
(Delayed Data from NSDQ)
$16.60 USD
+0.16 (0.97%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $16.61 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.60 USD
+0.16 (0.97%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $16.61 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Zacks News
Will Avadel Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Avadel Pharmaceuticals.
Jazz's (JAZZ) Sleep Drug Sunosi Nears Approval in Europe
by Zacks Equity Research
Jazz's (JAZZ) sleep drug, Sunosi, which is under review in Europe, receives recommendation for approval from the CHMP.
Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate
by Zacks Equity Research
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset
by Zacks Equity Research
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.
Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.
Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
by Zacks Equity Research
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
Do Options Traders Know Something About Avadel Pharmaceuticals (AVDL) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Avadel Pharmaceuticals (AVDL) stock based on the movements in the options market lately.
Jazz (JAZZ) Falls as Sleep Drug Gets Extended Review From FDA
by Zacks Equity Research
Jazz (JAZZ) announces that the FDA has extended the review period of its new drug application for sleep drug, solriamfetol, by three months to Mar 20, 2019.
Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) label expansion application for Xyrem in pediatric patients gets priority review from the FDA.
Avadel Pharmaceuticals (AVDL) Looks Good: Stock Up 5.3%
by Zacks Equity Research
Avadel Pharmaceuticals plc (AVDL) shares rose over 5% in the last trading session.
A Company's First Profit Can Mean Big Profits to Investors
by Kevin Matras
Kevin Matras screens for companies showing their 'first' profit, and explains why they are ones to watch. Highlighted stocks include FLML, CPHD and EFOI.